Skip Navigation



Annals of Oncology Advance Access published online on May 11, 2007
Annals of Oncology, doi:10.1093/annonc/mdm137
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/12/1943    most recent
mdm137v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bijelic, L
Right arrow Articles by Sugarbaker, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bijelic, L
Right arrow Articles by Sugarbaker, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

review

Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer

L Bijelic1, A Jonson2 and PH Sugarbaker1,*

1 Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington DC
2 Department of Women's Services, Washington Hospital Center, Washington DC, USA

* Correspondence to: Dr P. H. Sugarbaker, Peritoneal Surface Malignancy Program, 106 Irving Street, NW, Suite 3900N, Washington DC, USA 20010. Tel: +1-202-877-3908; Fax: +1-202-877-8602; E-mail: paul.sugarbaker{at}medstar.net

The aim of this systematic review is to critically evaluate cytoreductive surgery combined with heated intraoperative intraperitoneal chemotherapy in the treatment of ovarian cancer. A systematic review of all manuscripts published in the English literature that met predetermined inclusion criteria was carried out. Data concerning cytoreductive surgery, method and agents for administration of heated intraoperative intraperitoneal chemotherapy, morbidity, mortality, hospital stay and survival were extracted, critically reviewed and tabulated. Fourteen studies were analyzed. A wide variety of drug doses, methods of intraperitoneal chemotherapy administration and volume of chemotherapy solution were used. Seven studies showed that patients with complete cytoreduction had the greatest benefit. The median overall survival for primary and recurrent disease ranged from 22 to 54 months and the median disease-free survival from 10 to 26 months. The rates of significant morbidity associated with this combined treatment were low, ranging from 5% to 36%. The median mortality was 3% (range 0%–10%). Cytoreductive surgery combined with heated intraoperative intraperitoneal chemotherapy is a treatment option for patients with ovarian cancer that is worthy of further investigation. Selection criteria for patients most likely to benefit need to be defined.

cytoreductive surgery, heat, hyperthermia, intraperitoneal chemotherapy, ovarian cancer

Received for publication January 8, 2007. Revision received March 15, 2007. Accepted for publication March 22, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 In VivoHome page
F. CAVALIERE, D. GIANNARELLI, M. VALLE, O. FEDERICI, G. LIOTTA, P. PERRI, F. DI FILIPPO, A. GAROFALO, and P. IALONGO
Peritoneal Carcinomatosis from Ovarian Epithelial Primary: Combined Aggressive Treatment
In Vivo, May 1, 2009; 23(3): 441 - 446.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.